Molecular Oncology
Volume 1, Issue 3 , Pages 313-320 , December 2007

Use of high density antibody arrays to validate and discover cancer serum biomarkers

  • Christian M. Loch

      Affiliations

    • Molecular Diagnostics Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109-1024, USA
    • ,
  • Arturo B. Ramirez

      Affiliations

    • Molecular Diagnostics Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109-1024, USA
    • ,
  • Yan Liu

      Affiliations

    • Molecular Diagnostics Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109-1024, USA
    • ,
  • Cassandra L. Sather

      Affiliations

    • Genomics Shared Resource, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109-1024, USA
    • ,
  • Jeffrey J. Delrow

      Affiliations

    • Genomics Shared Resource, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109-1024, USA
    • ,
  • Nathalie Scholler

      Affiliations

    • Molecular Diagnostics Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109-1024, USA
    • ,
  • Barbara M. Garvik

      Affiliations

    • Molecular Diagnostics Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109-1024, USA
    • ,
  • Nicole D. Urban

      Affiliations

    • Molecular Diagnostics Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109-1024, USA
    • ,
  • Martin W. McIntosh

      Affiliations

    • Molecular Diagnostics Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109-1024, USA
    • ,
  • Paul D. Lampe

      Affiliations

    • Molecular Diagnostics Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109-1024, USA
    • Corresponding Author InformationCorresponding author. Fred Hutchinson Cancer Research Center, Public Health Sciences, 1100 Fairview Avenue North, M5C800, Box 19024, Seattle, WA 98109, USA. Tel.: +1 206 667 4123; fax: +1 206 667 2537.

Received 18 May 2007 ,Revised 22 August 2007 ,Accepted 23 August 2007.

References 

  1. Aebersold R, Anderson L, Caprioli R, Druker B, Hartwell L, Smith R. Perspective: a program to improve protein biomarker discovery for cancer. J. Proteome Res. 2005;4(4):1104–1109
  2. Angenendt P, Glokler J, Murphy D, Lehrach H, Cahill DJ. Toward optimized antibody microarrays: a comparison of current microarray support materials. Anal. Biochem. 2002;309(2):253–260
  3. Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J. Clin. Invest. 1981;68(5):1331–1337
  4. Bereczki E, Gonda S, Csont T, Korpos E, Zvara A, Ferdinandy P, et al. Overexpression of biglycan in the heart of transgenic mice: an antibody microarray study. J. Proteome Res. 2007;6(2):854–861
  5. Bi Q, Cen X, Wang W, Zhao X, Wang X, Shen T, et al. A protein microarray prepared with phage-displayed antibody clones. Biosens. Bioelectron. 2007;22(12):3278–3282
  6. Biade S, Marinucci M, Schick J, Roberts D, Workman G, Sage EH, et al. Gene expression profiling of human ovarian tumours. Br.J. Cancer. 2006;95(8):1092–1100
  7. Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin. Cancer Res. 2001;7(6):1661–1668
  8. Bratt T. Lipocalins and cancer. Biochim. Biophys. Acta. 2000;1482(1–2):318–326
  9. Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, et al Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med. 2006;3(3):e47
  10. Davidson B, Zhang Z, Kleinberg L, Li M, Florenes VA, Wang TL, et al. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma. Clin. Cancer Res. 2006;12(20 Pt 1):5944–5950
  11. Davis MA, Hanash S. High-throughput genomic technology in research and clinical management of breast cancer. Plasma-based proteomics in early detection and therapy. Breast Cancer Res. 2006;8(6):217
  12. Frank DE, Carter WG. Laminin 5 deposition regulates keratinocyte polarization and persistent migration. J. Cell Sci. 2004;117(Pt 8):1351–1363
  13. Gu Q, Sivanandam TM, Kim CA. Signal stability of Cy3 and Cy5 on antibody microarrays. Proteome Sci. 2006;4:21
  14. Haab BB, Dunham MJ, Brown PO. Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions. Genome Biol. 2001;2(2):research0004.1–0004.13
  15. Han MK, Hong MY, Lee D, Lee DE, Noh GY, Lee JH, et al. Expression profiling of proteins in L-threonine biosynthetic pathway of Escherichia coli by using antibody microarray. Proteomics. 2006;6(22):5929–5940
  16. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70
  17. Hartwell L, Mankoff D, Paulovich A, Ramsey S, Swisher E. Cancer biomarkers: a systems approach. Nat. Biotechnol. 2006;24(8):905–908
  18. Hellstrom I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003;63(13):3695–3700
  19. Ko IK, Kato K, Iwata H. Antibody microarray for correlating cell phenotype with surface marker. Biomaterials. 2005;26(6):687–696
  20. Lau AT, Chiu JF. The possible role of cytokeratin 8 in cadmium-induced adaptation and carcinogenesis. Cancer Res. 2007;67(5):2107–2113
  21. Lim R, Ahmed N, Borregaard N, Riley C, Wafai R, Thompson EW, et al. Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epithelio-mesenchymal transition. Int. J. Cancer. 2007;120(11):2426–2434
  22. Liu J, Guo Q, Chen B, Yu Y, Lu H, Li YY. Cathepsin B and its interacting proteins, bikunin and TSRC1, correlate with TNF-induced apoptosis of ovarian cancer cells OV-90. FEBS Lett. 2006;580(1):245–250
  23. MacBeath G, Schreiber SL. Printing proteins as microarrays for high throughput function determination. Science. 2000;289(5485):1760–1763
  24. McIntosh MW, Drescher C, Karlan B, Scholler N, Urban N, Hellstrom KE, et al. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol. Oncol. 2004;95(1):9–15
  25. McIntosh MW, Liu Y, Drescher C, Urban N, Diamandis EP. Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma. Clin. Cancer Res. 2007;13(15):4422–4428
  26. Miller JC, Zhou H, Kwekel J, Cavallo R, Burke J, Butler EB, et al. Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers. Proteomics. 2003;3(1):56–63
  27. Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, Rutherford T, et al. Serum protein markers for early detection of ovarian cancer. Proc. Natl. Acad. Sci. U.S.A. 2005;102(21):7677–7682
  28. Moubayed N, Weichenthal M, Harder J, Wandel E, Sticherling M, Glaser R. Psoriasin (S100A7) is significantly up-regulated in human epithelial skin tumours. J. Cancer Res. Clin. Oncol. 2007;133(4):253–261
  29. Orchekowski R, Hemelinck D, Li L, Gliwa E, vanBrocklin M, Marrero JA, et al. Antibody microarray profiling reveals individual and combined serum proteins associated with pancreatic cancer. Cancer Res. 2005;65(23):11193–11202
  30. Peluso P, Wilson DS, Do D, Tran H, Venkatasubbaiah M, Quincy D, et al Optimizing antibody immobilization strategies for the construction of protein microarrays. Anal. Biochem. 2003;312(2):113–124
  31. Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am. J. Epidemiol. 2004;159(9):882–890
  32. Smyth GK. Limma: linear models for microarray data. In:  Gentleman R,  Carey V,  Dudoit S,  Irizarry R,  Huber W editor. Bioinformatics and Computational Biology Solutions using R and Bioconductor. New York: Springer; 2005;p. 397–420
  33. Smyth GK, Speed T. Normalization of cDNA microarray data. Methods. 2003;31(4):265–273
  34. Sreekumar A, Nyati MK, Varambally S, Barrette TR, Ghosh D, Lawrence TS, et al. Profiling of cancer cells using protein microarrays: discovery of novel radiation-regulated proteins. Cancer Res. 2001;61(20):7585–7593
  35. States DJ, Omenn GS, Blackwell TW, Fermin D, Eng J, Speicher DW, et al. Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study. Nat. Biotechnol. 2006;24(3):333–338
  36. Steinhauer C, Wingren C, Khan F, He M, Taussig MJ, Borrebaeck CA. Improved affinity coupling for antibody microarrays: engineering of double-(His)6-tagged single framework recombinant antibody fragments. Proteomics. 2006;6(15):4227–4234
  37. Storey JD. The positive false discovery rate: a Bayesian interpretation and the q-value. Ann. Statist. 2003;31:2013–2035
  38. Storey JD, Taylor JE, Siegmund D. Strong control, conservative point estimation, and simultaneous conservative consistency of false discovery rates: a unified approach. J. Roy. Statist. Soc. Ser. B. 2004;66:187–205
  39. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U.S.A. 2005;102(43):15545–15550
  40. Treiber M, Schulz HU, Landt O, Drenth JP, Castellani C, Real FX, et al Keratin 8 sequence variants in patients with pancreatitis and pancreatic cancer. J. Mol. Med. 2006;84(12):1015–1022
  41. Usui-Aoki K, Shimada K, Koga H. A novel antibody microarray format using non-covalent antibody immobilization with chemiluminescent detection. Mol. Biosyst. 2007;3(1):36–42
  42. Vitzthum F, Behrens F, Anderson NL, Shaw JH. Proteomics: from basic research to diagnostic application. A review of requirements & needs. J. Proteome Res. 2005;4(4):1086–1097
  43. Wacker R, Schroder H, Niemeyer CM. Performance of antibody microarrays fabricated by either DNA-directed immobilization, direct spotting, or streptavidin-biotin attachment: a comparative study. Anal. Biochem. 2004;330(2):281–287
  44. Whiteaker JR, Zhang H, Eng JK, Fang R, Piening BD, Feng LC, et al. Head-to-head comparison of serum fractionation techniques. J. Proteome Res. 2007;6(2):828–836
  45. Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J. Pathol. 2003;200(3):290–297

PII: S1574-7891(07)00067-1

doi: 10.1016/j.molonc.2007.08.004

Molecular Oncology
Volume 1, Issue 3 , Pages 313-320 , December 2007

Article Tools

* Image Usage & Resolution